What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)
Read More 5 minute read Pharma Industry News EMA clears Curasight’s uTREAT trial—will targeted radiopharma redefine brain cancer therapy? Curasight wins EMA approval for its first uTREAT clinical trial in glioblastoma. Find out how its theranostic strategy could change brain cancer treatment. byPallavi MadhirajuAugust 26, 2025